Literature DB >> 31291759

Hepatic Forkhead Box Protein A3 Regulates ApoA-I (Apolipoprotein A-I) Expression, Cholesterol Efflux, and Atherogenesis.

Yuanyuan Li1, Yanyong Xu1, Kavita Jadhav1, Yingdong Zhu1, Liya Yin1, Yanqiao Zhang1.   

Abstract

OBJECTIVE: To determine the role of hepatic FOXA3 (forkhead box A3) in lipid metabolism and atherosclerosis. Approach and
Results: Hepatic FOXA3 expression was reduced in diabetic or high fat diet-fed mice or patients with nonalcoholic steatohepatitis. We then used adenoviruses to overexpress or knock down hepatic FOXA3 expression. Overexpression of FOXA3 in the liver increased hepatic ApoA-I (apolipoprotein A-I) expression, plasma HDL-C (high-density lipoprotein cholesterol) level, macrophage cholesterol efflux, and macrophage reverse cholesterol transport. In contrast, knockdown of hepatic FOXA3 expression had opposite effects. We further showed that FOXA3 directly bound to the promoter of the Apoa1 gene to regulate its transcription. Finally, AAV8 (adeno-associated virus serotype 8)-mediated overexpression of human FOXA3 in the hepatocytes of Apoe-/- (apolipoprotein E-deficient) mice raised plasma HDL-C levels and significantly reduced atherosclerotic lesions.
CONCLUSIONS: Hepatocyte FOXA3 protects against atherosclerosis by inducing ApoA-I and macrophage reverse cholesterol transport.

Entities:  

Keywords:  FOXA3; atherosclerosis; cholesterol efflux; liver; macrophages

Mesh:

Substances:

Year:  2019        PMID: 31291759      PMCID: PMC6656627          DOI: 10.1161/ATVBAHA.119.312610

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

1.  HDL and ASCVD.

Authors:  Hongtu Cui; Qian Du
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  FOXA3 Polymorphisms Are Associated with Metabolic Parameters in Individuals with Subclinical Atherosclerosis and Healthy Controls-The GEA Mexican Study.

Authors:  Gilberto Vargas-Alarcón; José Manuel Fragoso; Julian Ramírez-Bello; Rosalinda Posadas-Sánchez
Journal:  Biomolecules       Date:  2022-04-19

3.  CXCL12 promotes atherosclerosis by downregulating ABCA1 expression via the CXCR4/GSK3β/β-cateninT120/TCF21 pathway.

Authors:  Jia-Hui Gao; Lin-Hao He; Xiao-Hua Yu; Zhen-Wang Zhao; Gang Wang; Jin Zou; Feng-Jiao Wen; Li Zhou; Xiang-Jun Wan; Da-Wei Zhang; Chao-Ke Tang
Journal:  J Lipid Res       Date:  2019-10-29       Impact factor: 5.922

4.  Hydroxytyrosol Plays Antiatherosclerotic Effects through Regulating Lipid Metabolism via Inhibiting the p38 Signal Pathway.

Authors:  Xinxin Zhang; Yating Qin; Xiaoning Wan; Hao Liu; Chao Iv; Weibin Ruan; Li Lu; Lin He; Xiaomei Guo
Journal:  Biomed Res Int       Date:  2020-06-22       Impact factor: 3.411

5.  LncRNA TUG1 regulates ApoM to promote atherosclerosis progression through miR-92a/FXR1 axis.

Authors:  Liu Yang; Tie Li
Journal:  J Cell Mol Med       Date:  2020-06-28       Impact factor: 5.310

6.  Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism.

Authors:  Yanyong Xu; Yuanyuan Li; Kavita Jadhav; Xiaoli Pan; Yingdong Zhu; Shuwei Hu; Shaoru Chen; Liuying Chen; Yong Tang; Helen H Wang; Ling Yang; David Q-H Wang; Liya Yin; Yanqiao Zhang
Journal:  Nat Metab       Date:  2021-01-18

7.  Collapse of the hepatic gene regulatory network in the absence of FoxA factors.

Authors:  Yitzhak Reizel; Ashleigh Morgan; Long Gao; Yemin Lan; Elisabetta Manduchi; Eric L Waite; Amber W Wang; Andrew Wells; Klaus H Kaestner
Journal:  Genes Dev       Date:  2020-06-19       Impact factor: 12.890

Review 8.  High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential.

Authors:  Anne Jomard; Elena Osto
Journal:  Front Cardiovasc Med       Date:  2020-03-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.